Barclays Lifts Hims & Hers Price Target to $39 Despite 32% Short Interest
HIMS•Hims & Hers Health is extending its telehealth platform into GLP-1 treatments and international markets, operating with a $7.34 billion market cap. Barclays boosted its price target to $39 from $29 even as 30–32% short interest and $5.5 million in insider sales highlight potential headwinds.
1. Barclays Raises Price Target
On June 17, Barclays boosted its Hims & Hers price target to $39 from $29 while maintaining an Overweight rating, reflecting increased confidence in the telehealth company’s growth trajectory.
2. Telehealth Expansion and Partnerships
Hims & Hers is scaling its platform with a focus on GLP-1 medications and international markets, supporting a $7.34 billion market capitalization and forging partnerships with leading pharmaceutical firms.
3. Long-Term Financial Targets
Management is targeting at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, highlighting aggressive ambitions to expand subscriber base and enhance profitability.
4. Short Interest and Insider Activity
The stock faces significant challenges with 30–32% of shares sold short and $5.5 million in insider sales over three months, partially offset by $1.2 million in insider purchases.
